Skip to main content

FBRX

Stock
Health Care
Biotechnology

Performance overview

FBRX Price
Price Chart

Forward-looking statistics

Beta
1.39
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).

Company info

SectorHealth Care
IndustryBiotechnology
Employees12
Market cap$21.2M

Fundamentals

Enterprise value$39.3M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity0.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$9.51
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$1M
Avg trading volume (10 day)$3M
Put-call ratio

Macro factor sensitivity

Growth+7.3
Credit+0.5
Liquidity-6.3
Inflation+2.4
Commodities+1.6
Interest Rates-2.8

Valuation

Dividend yield0.00%
PEG Ratio-0.75
Price to sales
P/E Ratio-0.75
Enterprise Value to Revenue
Price to book2.34

Upcoming events

Next earnings dayAugust 12, 2025
Next dividend day
Ex. dividend day

News

All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to Buy

Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research (April 3, 2025)
Why Forte Biosciences Stock Is Down Over 80% Today

Forte Biosciences (NASDAQ: FBRX) is tanking today after the company announced the clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance. 'We are appreciative of the clinical trial sites and the patients for participating in this trial and we are grateful to our investors for taking the risk to support the advancement of a new therapeutic modality for atopic dermatitis,' said Paul Wagner, CEO of Forte Biosciences.

Benzinga (September 3, 2021)
A small biotech firm just plummeted 82% after abandoning a drug candidate due to failed phase 2 trial

The negative drug results led Chardan Capital Markets to slash its price target by 96% to $4 from $105.

Business Insider (September 3, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free